NCT01894919 - Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28 | Biotech Hunter

Enrollment

851

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

November 30, 2015

Conditions

Meningoccocal DiseaseMeningococcal Meningitis

Interventions

BIOLOGICAL

Bexsero® vaccine (1 dose at study month zero)

BIOLOGICAL

Bexsero® vaccine (2 doses 1 month apart)

Trial Locations (17)

1188

Site 40, General Pediatric Practice Hacsek, Budapest

3527

Site 30, General Practice Dr Simko, Miskolc

3534

Site 31, General Practice Dr Olga Fekete, Miskolc

4025

Site 34, General Pediatric Practice Somorjai, Debrecen

4400

Site 33, General Pediatric Practice Ujhelyi, Nyíregyháza

6640

Site 42, Praxis Dr Eszter Bari, Csongrád

6723

Site 35, Praxis Dr Eva Kovacs, Szeged

Site 36, General Practice Dr Edit Oszlacs, Szeged

6795

Site 37, Praxis Dr Julianna Kovacs, Bordány

15706

Site 10, Santiago de Compostela

28041

Site 17, Madrid

28935

Site 18, Madrid

36002

Site 13, Pontevedra

41014

Site 14, Seville

04007

Site 15, Almería

04120

Site 16, Almería

08195

Site 20, Barcelona